BIODEXA PHARMACEUTICALS-ADR (BDRX)
US59564R7089 - ADR
We assign a fundamental rating of 2 out of 10 to BDRX. BDRX was compared to 568 industry peers in the Biotechnology industry. BDRX may be in some trouble as it scores bad on both profitability and health. BDRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BDRX has reported negative net income.
In the past year BDRX has reported a negative cash flow from operations.
In the past 5 years BDRX always reported negative net income.
In the past 5 years BDRX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -48.82%, BDRX perfoms like the industry average, outperforming 48.67% of the companies in the same industry.
The Return On Equity of BDRX (-78.14%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.82% | ||
| ROE | -78.14% | ||
| ROIC | N/A |
ROA(3y)-82.67%
ROA(5y)-101.33%
ROE(3y)-148.56%
ROE(5y)-165.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BDRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BDRX has more shares outstanding
BDRX has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.38, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
BDRX has a Altman-Z score of -5.38. This is in the lower half of the industry: BDRX underperforms 63.36% of its industry peers.
BDRX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
BDRX has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: BDRX outperforms 42.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.38 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
A Current Ratio of 2.16 indicates that BDRX has no problem at all paying its short term obligations.
With a Current ratio value of 2.16, BDRX is not doing good in the industry: 73.98% of the companies in the same industry are doing better.
BDRX has a Quick Ratio of 2.16. This indicates that BDRX is financially healthy and has no problem in meeting its short term obligations.
BDRX has a worse Quick ratio (2.16) than 72.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.16 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
BDRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.74%, which is quite impressive.
Looking at the last year, BDRX shows a very negative growth in Revenue. The Revenue has decreased by -84.31% in the last year.
BDRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.56% yearly.
EPS 1Y (TTM)98.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.19%
Revenue 1Y (TTM)-84.31%
Revenue growth 3Y3.56%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
BDRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.16% yearly.
BDRX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -73.72% yearly.
EPS Next Y80.32%
EPS Next 2Y36.71%
EPS Next 3Y22.81%
EPS Next 5Y17.17%
Revenue Next Year-94.72%
Revenue Next 2Y-83.75%
Revenue Next 3Y-76.99%
Revenue Next 5Y-73.72%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BDRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BDRX's earnings are expected to grow with 22.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3Y22.81%
5. Dividend
5.1 Amount
No dividends for BDRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODEXA PHARMACEUTICALS-ADR
NASDAQ:BDRX (12/20/2024, 8:00:01 PM)
3.99
-0.01 (-0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.68%
Inst Owner Change104.49%
Ins Owners4.19%
Ins Owner ChangeN/A
Market Cap57.94M
Analysts85.71
Price Target204 (5012.78%)
Short Float %10%
Short Ratio0.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2400%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2400%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 557.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.3 | ||
| P/tB | 17.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.43
EYN/A
EPS(NY)-3.27
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.01
BVpS0.75
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.82% | ||
| ROE | -78.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-82.67%
ROA(5y)-101.33%
ROE(3y)-148.56%
ROE(5y)-165.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 402.54% | ||
| Cap/Sales | 1338.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.16 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | -5.38 |
F-Score2
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)46.48%
Cap/Sales(3y)44.42%
Cap/Sales(5y)48.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.19%
EPS Next Y80.32%
EPS Next 2Y36.71%
EPS Next 3Y22.81%
EPS Next 5Y17.17%
Revenue 1Y (TTM)-84.31%
Revenue growth 3Y3.56%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-94.72%
Revenue Next 2Y-83.75%
Revenue Next 3Y-76.99%
Revenue Next 5Y-73.72%
EBIT growth 1Y14.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.39%
OCF growth 3YN/A
OCF growth 5YN/A